Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
John J. Arcaroli(University of Colorado Denver), Wells A. Messersmith(University of Colorado Cancer Center)
Cited by 37
Related Papers
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2017|407
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|Annals of Oncology|2021|371
Variant IRAK-1 Haplotype is Associated with Increased Nuclear Factor–κB Activation and Worse Outcomes in Sepsis
|American Journal of Respiratory and Critical Care Medicine|2006|139